The expansion will allow the companies to shift from tissue to liquid biopsy. Credit: Tatiana from Pixabay.

IMBdx and AstraZeneca have expanded their collaboration agreement to promote the transition from tissue to liquid biopsy, following the successful assessment of a blood-based genomic profiling assay in prostate cancer.

This move will provide a wide range of options for patients with metastatic castration-resistant prostate cancer (mCRPC) through the AlphaLiquid HRR test, which is part of the PROSPER 2.0 project.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The AlphaLiquid HRR test is a next-generation sequencing-based test designed to assess plasma circulating tumour DNA (ctDNA) and report genomic modifications across all 15 homologous recombination repair (HRR) genes.

Currently, the assay is marketed in various international regions, including Colombia, Mexico, Lebanon, Ukraine, Australia, Taiwan, Malaysia, Vietnam, Saudi Arabia, Kuwait and the UAE.

The objective of this collaboration is to enhance the availability of targeted therapies for mCRPC patients in global markets beyond the US.

See Also:

IMBdx co-founder and CEO Dr Tae-You Kim said: “IMBdx developed the AlphaLiquid platform, a top-tier performance liquid biopsy test capable of detecting mutations at an exceptionally low level in human blood.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“We highly value our collaboration with AstraZeneca, which aims to make better clinical decisions that will ultimately benefit more cancer patients and improve their quality of life.”

Under the PROSPER 2.0 project, both entities are working together to enhance awareness among clinicians and patients about ctDNA testing’s clinical utility for mCRPC patients. It will help identify patients who can benefit from targeted therapies.

The companies are also focused on increasing awareness about the identification capability of HRR gene alterations through AlphaLiquid HRR ctDNA testing.